Findings

What do systematic reviews say?

1,549 questions · 1,604 findings · 181 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 258 · 16.1%GRADE not reported 69 · 4.3%Very low 337 · 21%Low 406 · 25.3%Moderate 410 · 25.6%High 124 · 7.7%

Intervention not reported

Total studies: 5 RCTs Total Participants: 5440 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5440 participants
GRADE not reported

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 1024 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1024 participants
Low

Intervention not reported

HD‐ICS/LABA (Direct evidence; 3 RCTs; 3152 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3152 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 2 RCTs; 1366 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1366 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 1379 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1379 participants
Moderate

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

Outcome№ of participants(studies)

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 3 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2450(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2450 participants
Moderate

Intervention not reported

CFB in ACQ at 3 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 768(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 764(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 771(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 767(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2079(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3 participants
Moderate

Intervention not reported

CFB in ACQ at 3 months ‐ TRIPLE vs DUAL№ of participants: 1535(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3762(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1961(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1952(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2561(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3459(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Low